Literature DB >> 1203841

Heparin and chemotherapy in the management of inoperable lung carcinoma.

E G Elias, S K Shukla, I B Mink.   

Abstract

Twenty-eight patients with inoperable or metastatic carcinoma of the lung who failed to respond to conventional chemotherapy and/or radiotherapy were entered in this study. All of them received repeated courses of multiple chemotherapy (cyclophosphamide, 5-fluorouracil, 6-thioguanine, methotrexate, and vincristine) with or without concurrent intravenous heparin anticoagulation. No tumor regression was noted in any of the 14 patients who received the multiple chemotherapy only. On the contrary, tumor progression was seen in all of them, and subsequently 12 died of their disease. The other 14 patients were anticoagulated with heparin, then received the same multiple chemotherapeutics while anticoagulated. Over 50% tumor regression was noted clinically and radiologically, and occasionally demonstrated histologically in 7 of them. Two patients in this group are alive and well for 1 1/2 years. No increase in toxicity or metastases was noted. The 2 patients who had progression of their disease while on the multiple chemotherapy program alone showed tumor regression when they received the same chemotherapy after heparinization.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1203841     DOI: 10.1002/1097-0142(197507)36:1<129::aid-cncr2820360109>3.0.co;2-s

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  14 in total

1.  [Combination chemotherapy in patients with disseminated bronchogenic carcinoma (author's transl)].

Authors:  C Gropp; K Havemann; W D Gassel; F Hess; R Prignitz; M Schmidt; C P Sodomann
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1977-12-15

Review 2.  Update in cancer chemotherapy, Part IV. Lung cancer, Part 2.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1985-11       Impact factor: 1.798

3.  Abnormal haemostasis in small cell lung cancer.

Authors:  R Milroy; J T Douglas; J Campbell; R Carter; G D Lowe; S W Banham
Journal:  Thorax       Date:  1988-12       Impact factor: 9.139

4.  Anticoagulants in the treatment of small cell carcinoma of the bronchus.

Authors:  C F Stanford
Journal:  Thorax       Date:  1979-02       Impact factor: 9.139

Review 5.  Treatment of cancer with anticoagulants: rationale in the treatment of melanoma.

Authors:  D L Ornstein; L R Zacharski
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

6.  Fibrinolytic Enzyme Cotherapy Improves Tumor Perfusion and Therapeutic Efficacy of Anticancer Nanomedicine.

Authors:  Ameya R Kirtane; Tanmoy Sadhukha; Hyunjoon Kim; Vidhi Khanna; Brenda Koniar; Jayanth Panyam
Journal:  Cancer Res       Date:  2017-01-20       Impact factor: 12.701

Review 7.  Prophylactic and therapeutic anticoagulation for thrombosis: major issues in oncology.

Authors:  Marc Carrier; Agnes Y Y Lee
Journal:  Nat Clin Pract Oncol       Date:  2008-10-28

8.  Sucrose octasulfate regulates fibroblast growth factor-2 binding, transport, and activity: potential for regulation of tumor growth.

Authors:  Michael Fannon; Kimberly Forsten-Williams; Matthew A Nugent; Kalvin J Gregory; Chia Lin Chu; Adrienne L Goerges-Wildt; Dipak Panigrahy; Arja Kaipainen; Carmen Barnes; Cathy Lapp; Yuen Shing
Journal:  J Cell Physiol       Date:  2008-05       Impact factor: 6.384

Review 9.  Inhibition of the arrest of hematogenously disseminated tumor cells.

Authors:  E Tsubura; T Yamashita; S Sone
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

10.  Can LMWH improve the outcome of patients with inoperable stage III non-small cell lung cancer?

Authors:  Mehmet Kucukoner; Abdurrahman Isikdogan; Muhammed Ali Kaplan; Ali Inal; S Zinciroglu; Murtaza Cit; Timucin Cil; Bilgehan Karadayi; Ahmet Dirier; Ismail Yildiz
Journal:  Contemp Oncol (Pozn)       Date:  2012-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.